Over 40 companies advance complement inhibitors targeting rare diseases in clinical trials

The complement inhibitors market is expanding as more companies recognize the complement system's role in diseases like paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Over 40 companies are developing more than 50 complement inhibitors. Recent developments include Q32 Bio presenting data on ADX-097 at a major nephrology conference, and ReAlta Life Sciences starting a Phase II study for RLS-0071. Other companies, like Annexon and Dianthus Therapeutics, reported positive trial results and FDA approvals for their drugs. The report highlights a growing pipeline of complement inhibitors targeting various diseases, with advancements in understanding complement biology driving new therapeutic options. This area of research is expected to continue evolving, addressing both rare and more common conditions.